Every Form 4 that BeyondSpring Inc. (BYSI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BYSI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BYSI filings page.
BeyondSpring Inc. director Majeti Jiangwen received a grant of stock options to buy 100,000 ordinary shares. The options carry an exercise price of $1.75 per share and expire on July 1, 2036.
According to the grant terms, the options vest in four equal 25% installments on the first, second, third and fourth anniversaries of July 1, 2026, as long as the director continues to serve the company. This is a compensation-related award rather than an open-market share purchase or sale.
BeyondSpring Inc. granted its Chief Executive Officer, Qiu Min, stock options as part of compensation. The award covers 100,000 stock options to purchase ordinary shares at an exercise price of $1.75 per share, expiring on July 1, 2036.
The options were granted for no cash cost to the CEO and will vest in four equal 25% installments on the first, second, third, and fourth anniversaries of July 1, 2026, contingent on continued service with the company. Following this grant, the filing shows 100,000 derivative securities held from this award.
BeyondSpring Inc. director and CEO Lan Huang reported an indirect transfer of 260,582 Ordinary Shares as a bona fide gift by the Lan Huang 2022 Grantor Retained Annuity Trust, leaving that trust with no shares. Other indirect holdings remain, including 253,465 shares held by the 2026 SUNSHINE GRAT and 223,291 shares held by the 2024 SPIRIT GRAT for the benefit of Dr. Huang’s children.
BeyondSpring Inc. director Matthew Kirkby received a grant of stock options covering 23,902 ordinary shares. The options have an exercise price of $1.64 per share and expire on April 1, 2036. All options vest on April 1, 2027, contingent on his continuous service with the company.
BeyondSpring Inc. director Patrick Fabbio received a grant of stock options covering 22,165 ordinary shares. The options have an exercise price of $1.64 per share and were issued under the company’s 2017 Omnibus Incentive Plan as part of his compensation.
All 22,165 options vest on April 1, 2027, provided he continues serving the company through that date, and they expire on April 1, 2036. This is a compensation-related award, not an open-market purchase or sale of BeyondSpring shares.
BeyondSpring Inc. director Brendan Delaney received a grant of stock options for 20,427 ordinary shares on April 1, 2026 as equity compensation. The options have an exercise price of $1.64 per share and expire on April 1, 2036. All options vest on April 1, 2027, subject to his continuous service with the company through that date.
BeyondSpring Inc. director Majeti Jiangwen received a grant of stock options to purchase 21,730 Ordinary Shares of the company. These options have an exercise price of $1.64 per share and expire on April 1, 2036.
All of the options will vest on April 1, 2027, provided the director continues to serve the company through that date. Following this grant, the Form 4 shows holdings of 21,730 stock options directly owned.
BeyondSpring Inc. reported that Chief Scientific Officer Lu Yingjuan June received a grant of stock options for 17,840 ordinary shares. The options have an exercise price of $1.64 per share and expire on April 1, 2036.
According to the grant terms, 4,460 options will vest on each of April 1, 2027, April 1, 2028, April 1, 2029 and April 1, 2030, as long as she continues serving the company through those dates. All options were reported as directly owned following this award.
BeyondSpring Inc. director and Chief Executive Officer Huang Lan received a grant of stock options to acquire 11,514 Ordinary Shares. The options have an exercise price of $1.804 per share and were awarded at no cost to the reporting person.
According to the grant terms, 2,878 options will vest on each of April 1, 2027, April 1, 2028 and April 1, 2029, and 2,880 options will vest on April 1, 2030, subject to continuous service with the company. The options expire on April 1, 2031. This is a compensation-related award rather than an open-market purchase or sale.
Xu Sihai reported acquisition or exercise transactions in this Form 4 filing.
BeyondSpring Inc. director Xu Sihai received a grant of stock options covering 18,689 ordinary shares. The options have a strike price of $1.64 per share and expire on April 1, 2036.
According to the grant terms, all of these stock options vest on April 1, 2027, provided Xu continues to serve with the company through that date. This award increases his directly held derivative position to 18,689 options and reflects compensation rather than an open-market purchase or sale.
BeyondSpring (BYSI): Decheng Capital–affiliated reporting persons, identified as a director, reported open-market sales of ordinary shares. On 10/16/2025, Fund III sold 85,798 shares at a weighted average price of $1.72 (prices ranged from $1.62 to $1.795). On 10/17/2025, Fund III sold 45,513 shares at a weighted average price of $1.76 (prices ranged from $1.73 to $1.80).
Following these transactions, Fund III reported 1,518,893 shares beneficially owned indirectly. Separate indirect holdings reported were 1,617,409 shares by Fund II and 891,734 shares by the Global Healthcare Fund. The sales were executed across multiple prices, with full trade breakdowns available upon request as noted in the footnotes.
BeyondSpring (BYSI) reported insider transactions by Decheng Capital–affiliated funds. Decheng Capital China Life Sciences USD Fund III, L.P. reported sales of 107,361 ordinary shares on 10/13/2025 at a weighted average price of $1.70 (range $1.69–$1.75), 28,495 shares on 10/14/2025 at $1.65 (range $1.62–$1.70), and 17,960 shares on 10/15/2025 at $1.65 (range $1.60–$1.685). Following these trades, Fund III reported 1,650,204 shares indirectly held. Other reported indirect holdings were 1,617,409 shares by Fund II and 891,734 shares by the Global Healthcare Fund.
Decheng Capital affiliates and Dr. Xiangmin Cui reported insider sales of BeyondSpring Inc. (BYSI) ordinary shares across three trading dates. Fund III sold 7,507 shares on 10/08/2025 at a weighted average price of $1.77, 3,979 shares on 10/09/2025 at a weighted average price of $1.81, and 2,390 shares on 10/10/2025 at a weighted average price of $1.77, totaling 13,876 shares sold. After these transactions, Fund III reports beneficial ownership of 1,804,020 shares. Related Decheng entities report additional indirect holdings of 1,617,409 and 891,734 shares respectively, held by Fund II and the Global Healthcare master fund. The filing discloses that reported prices are weighted averages across specified price ranges and that general partners and Dr. Cui may be deemed to beneficially own the funds' holdings while disclaiming direct ownership beyond pecuniary interest.
BeyondSpring Inc. (BYSI): Decheng Capital-affiliated reporting persons disclosed open-market sales of ordinary shares. On 10/03, 600 shares were sold at $1.76 (weighted average range $1.73–$1.79); on 10/06, 17,500 shares at $1.78 (range $1.73–$1.7879); and on 10/07, 2,100 shares at $1.79 (range $1.74–$1.80). The filing is made by more than one reporting person, noted as Director and 10% Owner.
Following these transactions, indirect beneficial holdings were reported as 1,817,896 shares by Decheng Capital China Life Sciences USD Fund III, L.P., 1,617,409 shares by Decheng Capital China Life Sciences USD Fund II, L.P., and 891,734 shares by Decheng Capital Global Healthcare Fund (Master), LP.
Decheng Capital reporting persons, including funds managed by Dr. Xiangmin Cui, disclosed insider sales of 7,665 BeyondSpring Inc. (BYSI) ordinary shares across three days. The filings show 4,464 shares sold on 09/30/2025 at a weighted average price of about $1.81, 2,601 shares sold on 10/01/2025 at about $1.80, and 600 shares sold on 10/02/2025 at about $1.73. After the reported transactions, Decheng Capital China Life Sciences USD Fund III, L.P. is shown as beneficially owning approximately 1,838,096–1,841,297 shares (per line entries), while affiliated funds report holdings of 1,617,409 and 891,734 shares respectively. The footnotes state the prices are weighted averages within disclosed ranges and confirm the reporting chain through GP entities managed by Dr. Cui.
Decheng Capital entities disclosed multiple small sales of BeyondSpring Inc. (BYSI) ordinary shares in late September 2025. Fund III sold 1,800 shares on 09/25/2025 through 09/29/2025 in three reported transactions (700 at a weighted average $1.66, 600 at $1.68, 500 at $1.75), reducing Fund III's reported holdings to 1,845,761 shares after the last sale. Related Decheng entities report additional indirect holdings of 1,617,409 shares (Fund II) and 891,734 shares (Global Healthcare Master).
The filings identify Decheng Capital Management III (GP III) and Dr. Xiangmin (Cui) as manager/related parties and state that GP and Dr. Cui may be deemed beneficial owners of the funds' holdings but disclaim direct ownership except for pecuniary interest. The transactions are reported as sales with weighted average price ranges disclosed in footnotes.